ImmunoGen, Inc. - Common Stock (NQ:IMGN)

N/A UNCHANGED

Last Price Updated: 4:00 PM EST, Feb 9, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ImmunoGen, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

ImmunoGen to Present Initial Data Combining IMGN632 with Vidaza® and Venclexta® in Relapsed/Refractory Acute Myeloid Leukemia at ASH

November 04, 2021

From ImmunoGen

Via Business Wire

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 01, 2021

From ImmunoGen Inc.

Via Business Wire

ImmunoGen, inc (IMGN) Q3 2021 Earnings Call Transcript ↗

October 29, 2021

IMGN earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

The Daily Biotech Pulse: Gilead-Merck Collaborate For Breast Cancer Study, Decision Day For ANI Pharma, Pfizer Gets Canadian Regulatory Nod, 3 IPOs ↗

October 29, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Gilead, Merck to Study Trodelvy-Keytruda Combo For Breast Cancer Gilead, Inc...

Via Benzinga

Recap: Immunogen Q3 Earnings ↗

October 29, 2021

Immunogen (NASDAQ:IMGN) reported its Q3 earnings results on Friday, October 29, 2021 at 06:30 AM. Here's what investors need to know about the announcement. Earnings...

Via Benzinga

ImmunoGen Reports Recent Progress and Third Quarter 2021 Financial Results

October 29, 2021

From ImmunoGen Inc.

Via Business Wire

Earnings Outlook For Immunogen ↗

October 28, 2021

Immunogen (NASDAQ:IMGN) is set to give its latest quarterly earnings report on Friday, 2021-10-29. Here's what investors need to know before the announcement. Analysts...

Via Benzinga

Earnings Scheduled For October 29, 2021 ↗

October 29, 2021

Companies Reporting Before The Bell • Sify Technologies (NASDAQ:SIFY) is expected to report quarterly earnings at $0.02 per share on revenue of $97.70 million. •...

Via Benzinga

ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2021 Operating Results

October 14, 2021

From ImmunoGen Inc.

Via Business Wire

The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More ↗

October 24, 2021

Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength...

Via Benzinga

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 01, 2021

From ImmunoGen Inc.

Via Business Wire

ImmunoGen Appoints Helen M. Thackray, MD to its Board of Directors

September 22, 2021

From ImmunoGen Inc.

Via Business Wire

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 02, 2021

From ImmunoGen Inc.

Via Business Wire

ImmunoGen, inc (IMGN) Q2 2021 Earnings Call Transcript ↗

July 30, 2021

IMGN earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

Recap: Immunogen Q2 Earnings ↗

July 30, 2021

Shares of Immunogen (NASDAQ:IMGN) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share were down 7.14% year over year to ($0.15),...

Via Benzinga

The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs ↗

July 30, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

ImmunoGen Reports Recent Progress and Second Quarter 2021 Financial Results

July 30, 2021

From ImmunoGen Inc.

Via Business Wire

Earnings Scheduled For July 30, 2021 ↗

July 30, 2021

Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its second quarter. • Embraer (NYSE:ERJ) is...

Via Benzinga

The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More ↗

July 25, 2021

Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start...

Via Benzinga

ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2021 Operating Results

July 15, 2021

From ImmunoGen Inc.

Via Business Wire

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 01, 2021

From ImmunoGen Inc.

Via Business Wire

Immunogen Insights: Return On Capital Employed ↗

June 23, 2021

Immunogen (NASDAQ:IMGN) reported Q1 sales of $15.71 million. Earnings fell to a loss of $28.92 million, resulting in a 179.18% decrease from last quarter. Immunogen earned $36.52...

Via Benzinga

Immunogen Insights: Return On Capital Employed ↗

June 07, 2021

Immunogen (NASDAQ:IMGN) reported Q1 sales of $15.71 million. Earnings fell to a loss of $28.92 million, resulting in a 179.18% decrease from last quarter. Immunogen earned $36.52...

Via Benzinga

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 01, 2021

From ImmunoGen Inc.

Via Business Wire

The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes ↗

May 31, 2021

After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-...

Via Benzinga

ImmunoGen Announces Webcast of Presentation at Upcoming Jefferies Virtual Healthcare Conference

May 20, 2021

From ImmunoGen Inc.

Via Business Wire

ImmunoGen Announces Mature Data from FORWARD II Study Evaluating Mirvetuximab Soravtansine in Combination with Avastin® in Recurrent Ovarian Cancer, Regardless of Platinum Status

May 19, 2021

From ImmunoGen Inc.

Via Business Wire

Immunogen Inc (IMGN) Q1 2021 Earnings Call Transcript ↗

May 10, 2021

IMGN earnings call for the period ending March 31, 2021.

Via The Motley Fool

Topics Earnings

Immunogen: Q1 Earnings Insights ↗

May 10, 2021

Shares of Immunogen (NASDAQ:IMGN) decreased 1.8% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share were unchanged 0.00% over...

Via Benzinga

ImmunoGen Reports Recent Progress and First Quarter 2021 Financial Results

May 10, 2021

From ImmunoGen Inc.

Via Business Wire

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.